Rapid in-situ hybridization detection method and application thereof

Through the rapid in situ hybridization detection method and the use of anti-DNA-RNA hybrid mouse monoclonal antibodies, the problem of non-specific recognition in ELISA detection leads to high background value, achieving high specificity and high sensitivity DNA-RNA hybrids Combined detection, suitable for a variety of testing applications.

CN118962122AActive Publication Date: 2024-11-15HANGZHOU BAIYIN BIOTECHNOLOGY CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202411120702.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-15
Publication Date
2024-11-15
Estimated Expiration
2044-08-15

AI Technical Summary

Technical Problem

The existence of nonspecific recognition in the prior art in ELISA detection results in high background values, affecting the accuracy of the detection results.

Method used

Using rapid in situ hybridization detection method, anti-DNA-RNA hybrid mouse monoclonal antibody was used. This antibody was used to immunize animals, prepare hybridoma cell lines, obtain antibody sequences, express and purify, and combine dewaxing, protease digestion, and EBER detection. Needle hybridization, antibody immunity and DAB chromatography can achieve high specificity and sensitivity detection of DNA-RNA hybrids.

Benefits of technology

It improves the sensitivity and specificity of the detection, reduces the background value, and can accurately identify and detect specific DNA or RNA sequences in cells. It is suitable for fluorescence in situ hybridization detection, ELISA detection and other detection fields.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118962122A_ABST
    Figure CN118962122A_ABST
Patent Text Reader

Abstract

The embodiment of the invention relates to the technical field of nucleic acid detection, in particular to a rapid in-situ hybridization detection method and application thereof, and the rapid in-situ hybridization detection method comprises the following steps: S1, preparing an anti-DNA-RNA heterozygote antibody; s2, carrying out in-situ hybridization detection; the method comprises the steps of dewaxing, protease digestion, probe hybridization, anti-DNA-RNA heterozygote antibody immunization, DAB (or fast red) color development, hematoxylin dye liquor redyeing, blue returning, dehydration, transparentizing, conventional mounting and the like. According to the present invention, the monoclonal antibody against the DNA-RNA heterozygote mouse is matched, the combination of the antibody and the DNA-RNA heterozygote molecule has high specificity and high sensitivity, the DNA or RNA sequence specifically recognized by the probe in the cell can be specifically recognized and detected, and the positive high expression is provided during the DNA-RNA heterozygote detection; the antibody can be applied to the detection and screening fields of fluorescence in situ hybridization detection, ELISA detection, antibody chip preparation, flow cytometry and the like, and is beneficial to obtaining accurate evaluation and detection results.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The embodiments of the present invention relate to the technical field of antigen detection, and specifically to a rapid in situ hybridization detection method and application thereof. Background Art

[0002] The existing HPV probe (in situ hybridization) detection kit and EBER probe (in situ hybridization) detection kit adopt fluorescence in situ hybridization technology, use HPV probe (EBER probe) labeled with digoxin to hybridize and bind to specific target sequences in tissue cells, digoxin antibody reacts with HPV probe (EBER probe) to form immune complex, and uses enhanced secondary antibody reagent to bind to digoxin antibody-HPV probe (EBER probe) complex, and finally HRP catalyzes DAB to form brown-yellow precipitation at the binding site, thereby displaying specific target RNA sequence sites in cells under a microscope. This method adopts fluorescence in situ hybridization technology and uses enhanced secondary antibody for signal amplification. The method is time-consuming and has low specificity. The antibody involved in the rapid in situ hybridization method of the present invention does not need to use enhanced secondary antibody, and directly uses the complex of antibody and AP to detect DNA-RNA hybrid, and finally catalyzes the substrate to emit light. This antibody has a strong ability to bind DNA-RNA hybrid. The use of this antibody shortens the reaction time and improves the sensitivity and specificity of detection.

[0003] The S9.6 mouse monoclonal antibody was generated in 1986 in mice immunized with bacteriophage φX174, a genome-long DNA-RNA hybrid. The resulting S9.6 has high affinity and specificity for DNA-RNA hybrids, while having low affinity for double-stranded RNA (dsRNA) and no affinity for single-stranded DNA (ssDNA) or single-stranded RNA (ssRNA). Because of its unique properties, the S9.6 immunoglobulin provides the basis for many applications including solution recognition of DNA-RNA hybrids, undetected transcriptionally active genomic regions, in vitro and in vivo recognition of R-loops (single-stranded genomic DNA annealing to nascent mRNA) in transcribing cells, and label-free miRNA (a class of non-coding single-stranded RNA molecules of approximately 22 nucleotides in length encoded by endogenous genes, which are involved in post-transcriptional gene expression regulation in animals and plants) detection analysis.

[0004] Although the S9.6 mouse monoclonal antibody in the prior art has higher specificity and sensitivity to DNA-RNA hybrids than antibodies on the market, it still has non-specific recognition when performing ELISA detection, resulting in a high background value. Therefore, screening an anti-DNA-RNA hybrid antibody with a low background value is of great significance for the detection of viruses and tumor cells. In view of this, we propose a rapid in situ hybridization detection method and its application. Summary of the invention

[0005] The purpose of the embodiments of the present invention is to provide a rapid in situ hybridization detection method and its application, which solves the problem in the prior art that nonspecific recognition still exists when performing ELISA detection, resulting in a high background value.

[0006] To achieve the above objectives, the embodiments of the present invention provide the following technical solutions:

[0007] A rapid in situ hybridization detection method and application thereof, comprising the following steps:

[0008] S1. Preparation of anti-DNA-RNA hybrid antibody; the anti-DNA-RNA hybrid antibody is an anti-DNA-RNA hybrid mouse monoclonal antibody, which can specifically recognize any DNA-RNA hybrid to generate an antigen-antibody immune reaction; the heavy chain encoding gene for encoding the anti-DNA-RNA hybrid mouse monoclonal antibody in step S1 is SEQID1,

[0009] CAGGTGCAGCTGCAGCAGAGCGGCCCGGAACTGGTGAAACCGGGCGCGAGCGTGAAAATGAGCTGC

[0010] AAAGCGAGCGGCTATAACCTTTACCAGCCTGCGCATTACCGATTGGGTGAAACAGAAACCGGGCCAG

[0011] GGCCTGGAATGGATTGGCGATGTGAGCAGCAAAAAAGAACTGGATAAAAGCCAGGAAAAAAGAAGAA

[0012] GTGCAGACCAAAGCGACCCTGACCAGCGATAAAAGCAGCAGCACCGCGTATATGGAACTGAGCAGC

[0013] CTGACCAGCAAAGATAGCGCGGTGTATTATTGCGCGCGCCAGCATAAAAGCGAAGAAGATATTCTGGCGTGGGGCCAGGGCACCACCCTGACCGTGAGCAGC;

[0014] The light chain encoding gene is SEQ ID 2,

[0015] GATATTGTGATGACCCAGACCCCGCTGAGCCTGCCGGTGAGCCTGGGCGATCAGGCGAGCATTAGC

[0016] TGCAACATTTGCCGCAACTGCCAGTGCCTGAGCTGCATGGATTGCGGCAAAGATTTTTGGTATCTG

[0017] CAGAAACCGGGCCAGAGCCCGAAACTGCTGATTTATAGCGAAGATCAGAAATATGGCGGCAAAGAT

[0018] GGCGTGCCGGATCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCCTGAAAATTAGCCGCGTG

[0019] GAAGCGGAAGATCTGGGCGTGTATTATTGCGGCAAAGAAAGCCTGGAAAACGAATTTGAAATTTTT

[0020] GGCGGCGGCACCAAACTGGAAATTAAACGCGGCGGCGGCGGCAGCGGCGGCGGCGGCAGCGGCGGCGGCGGCAGCGGCGGCGGCGGCAGC;

[0021] The heavy chain amino acid sequence of the anti-DNA-RNA hybrid antibody is SEQ ID 3, QVQLQQSGPELVKPGASVKMSCKASGYTFTSLRITDWVKQKPGQGLEWIGDVSSKKELDKSQEKEE VQTKATLTSDKSSSTAYMELSSLTSKDSAVYYCARQHKSEEDILAWGQGTTLTVSS;

[0022] The light chain amino acid sequence is SEQ ID 4,

[0023] DIVMTQTPLSLPVSLGDQASISCNICRNCQCLSCMDCGKDFWYLQKPGQSPKLLIYSEDQKYGGKD

[0024] GVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCGKESLENEFEIFGGGTKLEIKRGGGGSGGGGSGGGGSGGGGS.

[0025] The preparation of the anti-DNA-RNA hybrid antibody in step S1 comprises the following steps:

[0026] S1.1. Immunization of animals: 100 μg / ml DNA-RNA hybrid and 100 μg / ml methylated bovine serum albumin were mixed in a 10 mM TE buffer at a mass ratio of 1:1, 30 μg DNA-RNA hybrid was emulsified with Freund's complete adjuvant for each Balb / c mouse, and injected subcutaneously in the abdomen. On the 14th and 28th days, booster immunizations were performed (using the same dose as the initial immunization and emulsified with Freund's incomplete adjuvant). On the 35th day, blood was collected from the mouse tail for detection;

[0027] S1.2, preparing hybridoma cell lines; taking immune mouse lymphocytes and performing cell fusion and cloning screening to obtain positive hybridoma stable cell lines that can efficiently secrete antibodies, and isolating total RNA from the hybridoma cell lines;

[0028] S1.3, obtaining antibody sequences; reverse transcribing the total RNA into cDNA, and using specific primers to obtain the nucleotide sequences of the antibody heavy chain variable region and the antibody light chain variable region through PCR amplification technology;

[0029] S1.4, antibody expression and purification: cloning the nucleotide sequence into an expression vector, transiently transfecting cultured cells using a transfection method, collecting the supernatant after culture, and purifying the supernatant using Protein A to obtain an antibody with a purity of >95%;

[0030] S2, rapid in situ hybridization test;

[0031] The rapid in situ hybridization detection in step S2 includes the following detection steps:

[0032] S2.1, dewaxing; drying the tissue slices in a 75°C oven, dewaxing in a dewaxing solution for 5 min × 3 times, treating with 100% alcohol for 3 min × 2 times, treating with 95% alcohol for 2 min, treating with 85% alcohol for 2 min, and soaking in purified water for 2 min; the main component of the dewaxing solution is xylene, and the slices need to be soaked in three cylinders of xylene solution for 5 min in sequence;

[0033] S2.2, protease digestion; shake off the water on the glass slide, draw circles around the tissue with a water-blocking pen, and use PBST to wash for 1min×3 times; then add 50-100μl of protease digestion solution, incubate at 37℃ for 10-20min; pour out the protease digestion solution, and then wash with PBST for 2min×3 times; the water-blocking pen is an oily pen, which is used to lock the buffer solution and working solution added subsequently; the concentration of the PBST cleaning solution is 0.01mol / L, and the components of 1L solution are as follows: 5.82g sodium chloride; 38.81g disodium hydrogen phosphate dodecahydrate; 15.60g sodium dihydrogen phosphate dihydrate; 200μl Tween 20; pH value is 7.2-7.4; the protease digestion solution is a solid protease dissolved in TBS solution, and the BSA solution is 100ml of 0.5mol / L Tris-HCl buffer, 3.5g NaCl (0.15mol / L), added to make up to 1000ml;

[0034] S2.3, EBER probe hybridization; according to the size of the tissue, 100-150 μl of EBER probe was added dropwise, placed in a wet box, hybridized and incubated at 37°C for 1-2 hours, and then washed with PBST for 2 minutes × 3 times; the EBER probe is a DNA sequence complementary to the EB virus-specific target, which is a protective sequence with a length of 35 bp; the EBER probe is 20-100 bp in length, and the EBER probe in step S2.3 is one of 15 bp, 35 bp, 100 bp, 500 bp, 1000 bp, and 2000 bp in length; the wet box is kept away from light during use, and the color of the wet box is brown or black;

[0035] S2.4, anti-DNA-RNA hybrid antibody immunization; remove PBST buffer, add 50-100μl of HRP enzyme-labeled anti-DNA-RNA hybrid antibody to each slice, and incubate at 37°C for 30min; after the incubation is completed, rinse with PBST buffer for 2min×3 times; the antibody is purified by Protien G column, and the antibody diluent is diluted 1000 times before use, and the antibody diluent components are: sodium chloride 2.535-3.501g; Tris-HCl buffer 6-7ml; casein solution 20-28ml; preservative 28-31μl; the balance is pure water; the pH value of Tris-HCl is 7.4-7.5; the antibody is an anti-DNA-RNA antibody, and the antibody is coupled with horseradish peroxidase (HRP), and the HRP can make the DAB color developing solution form a brown precipitate;

[0036] S2.5, DAB color development; remove PBST buffer, add 100-150 μl of freshly prepared DAB color development solution (DAB concentrate:DAB buffer=1:19) to each slice, and color development at room temperature for 3-5 minutes; the DAB color development solution must be prepared and used immediately, and the preparation time should not exceed 1 hour; the main component of the DAB color development solution is diaminobenzidine, and the DAB color development solution and DAB diluent must be stored in the dark;

[0037] S2.6, counterstain with hematoxylin; rinse with tap water, add 100-150μl of hematoxylin counterstain, incubate for 1-3min, rinse with tap water to turn blue; dehydrate the sections, make them transparent, and seal them conventionally; observe the staining of the tissue to be tested under an optical microscope;

[0038] A rapid in situ hybridization detection application includes the application of a rapid in situ hybridization detection method in the detection of anti-DNA-RNA hybrid antibody protein molecules.

[0039] By means of the above technical solution, the present invention provides a rapid in situ hybridization detection method and its application, which has at least the following beneficial effects:

[0040] (1) The present invention uses the steps of dewaxing, protease digestion, EBER probe hybridization, anti-DNA-RNA hybrid antibody immunization, fast red color development, hematoxylin staining, blueing, dehydration, transparency, conventional sealing, etc. in combination with anti-DNA-RNA hybrid mouse monoclonal antibody. The antibody binds to the DNA-RNA hybrid molecule with high specificity and high sensitivity, and can specifically identify and detect the DNA or RNA sequence in the cell that is specifically recognized by the probe. It is positive and highly expressed when detecting DNA-RNA hybrids. Therefore, the antibody can be applied to detection and screening fields such as fluorescence in situ hybridization detection, ELISA detection, antibody chip preparation, flow cytometry, etc., which is conducive to obtaining accurate evaluation and detection results.

[0041] (2) The anti-DNA-RNA hybrid mouse monoclonal antibody of the present invention has a relatively sensitive specific binding ability. The antibody can be labeled with alkaline phosphatase or horseradish peroxidase, and has a very high detection sensitivity under the condition of extremely low concentration in the working solution, and the detection background value is low. The antibody can be used as the first antibody and the second antibody simultaneously in the hybridization capture-chemiluminescence method, and has a very high application value. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] The accompanying drawings described herein are used to provide a further understanding of the present invention and constitute a part of this application:

[0043] Figure 1 The detection result of DAB staining of the EBER rapid in situ hybridization detection reagent in the present invention;

[0044] Figure 2 The detection result of the EBER in situ hybridization method detection reagent in the prior art;

[0045] Figure 3 The result of the EBER rapid in situ hybridization method detection reagent fast red staining in the present invention; DETAILED DESCRIPTION

[0046] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0047] A rapid in situ hybridization detection method and application thereof, comprising the following steps:

[0048] S1. Preparation of anti-DNA-RNA hybrid antibody; the anti-DNA-RNA hybrid antibody is an anti-DNA-RNA hybrid mouse monoclonal antibody, which can specifically recognize any DNA-RNA hybrid and generate antigen-antibody immune reaction with any DNA-RNA hybrid;

[0049] The preparation of the anti-DNA-RNA hybrid antibody in step S1 comprises the following steps:

[0050] S1.1. Immunization of animals: 100 μg / ml DNA-RNA hybrid and 100 μg / ml methylated bovine serum albumin were mixed in a 10 mM TE buffer at a mass ratio of 1:1, 30 μg DNA-RNA hybrid was emulsified with Freund's complete adjuvant for each Balb / c mouse, and injected subcutaneously in the abdomen. On the 14th and 28th days, booster immunizations were performed (using the same dose as the initial immunization and emulsified with Freund's incomplete adjuvant). On the 35th day, blood was collected from the mouse tail for detection;

[0051] S1.2, preparing hybridoma cell lines; taking immune mouse lymphocytes and performing cell fusion and cloning screening to obtain positive hybridoma stable cell lines that can efficiently secrete antibodies, and isolating total RNA from the hybridoma cell lines;

[0052] S1.3, obtaining antibody sequences; reverse transcribing the total RNA into cDNA, and using specific primers to obtain the nucleotide sequences of the antibody heavy chain variable region and the antibody light chain variable region through PCR amplification technology;

[0053] S1.4. Antibody expression and purification: clone the nucleotide sequence into an expression vector, transiently transfect the cultured cells using a transfection method, collect the supernatant after culture, and purify the supernatant using Protein A to obtain an antibody with a purity of >95%;

[0054] S2, rapid in situ hybridization test;

[0055] The rapid in situ hybridization detection in step S2 includes the following detection steps:

[0056] S2.1, dewaxing; drying the tissue sections in a 75℃ oven, dewaxing in a dewaxing solution for 5min×3 times, treating with 100% alcohol for 3min×2 times, treating with 95% alcohol for 2min, treating with 85% alcohol for 2min, and soaking in purified water for 2min; the main component of the dewaxing solution is xylene, and the sections need to be soaked in three cylinders of xylene solution for 5min in turn;

[0057] S2.2, protease digestion; shake off the water on the slide, draw circles around the tissue with a water-blocking pen, and use PBST to wash for 1min×3 times; then add 50-100μl of protease digestion solution, incubate at 37℃ for 10-20min; pour out the protease digestion solution, and then wash with PBST for 2min×3 times; the water-blocking pen is an oily pen, which is used to lock the buffer solution and working solution added later; the concentration of PBST cleaning solution is 0.01mol / L, and the components of 1L solution are as follows: 5.82g sodium chloride; 38.81g disodium hydrogen phosphate dodecahydrate; 15.60g sodium dihydrogen phosphate dihydrate; 200μl Tween 20; pH value is 7.2-7.4; protease digestion solution is protease solid dissolved in TBS solution, BSA solution is 100ml 0.5mol / L Tris-HCl buffer, 3.5g NaCl (0.15mol / L), add to make up to 1000ml;

[0058] S2.3, EBER probe hybridization; according to the size of the tissue, add 100-150μl EBER probe, place in a wet box, incubate at 37℃ for 1-2h, and then wash with PBST for 2min×3 times; the EBER probe is a DNA sequence complementary to the EB virus specific target, which is a protection sequence with a length of 35bp; the EBER probe length is 20-100bp, and the EBER probe length in step S2.3 is one of 15bp, 35bp, 100bp, 500bp, 1000bp, and 2000bp; the wet box is kept away from light during use, and the color of the wet box is brown or black;

[0059] S2.4, anti-DNA-RNA hybrid antibody immunization; remove PBST buffer, add 50-100μl of HRP enzyme-labeled anti-DNA-RNA hybrid antibody to each slice, and incubate at 37℃ for 30min; after incubation, rinse with PBST buffer for 2min×3 times; the antibody is purified by Protien G column, and the antibody diluent is diluted 1000 times before use. The components of the antibody diluent are: 2.535-3.501g of sodium chloride; 6-7ml of Tris-HCl buffer; 20-28ml of casein solution; 28-31μl of preservative; the remainder is pure water; the pH value of Tris-HCl is 7.4-7.5; the antibody is an anti-DNA-RNA antibody, and the antibody is coupled with horseradish peroxidase (HRP), and the HRP can make the DAB color developing solution form a brown precipitate;

[0060] S2.5, DAB color development; remove PBST buffer, add 100-150 μl of freshly prepared DAB color development solution (DAB concentrate:DAB buffer = 1:19) to each slice, and color development at room temperature for 3-5 minutes; DAB color development solution must be prepared and used immediately, and the preparation time should not exceed 1 hour; the main component of DAB color development solution is diaminobenzidine, and both DAB color development solution and DAB diluent must be stored in the dark;

[0061] S2.6, counterstain with hematoxylin; rinse with tap water, add 100-150μl of hematoxylin counterstain, incubate for 1-3min, rinse with tap water to turn blue; dehydrate the sections, make them transparent, and seal them conventionally; observe the staining of the tissue to be tested under an optical microscope;

[0062] Example

[0063] The anti-DNA-RNA hybrid antibody obtained by the method in step S1 is applied to the HPV chemiluminescence-hybridization capture detection reagent after AP labeling, and the sample to be detected is detected by the detection reagent. The operation steps are as follows:

[0064] Step 1, denaturation: the cells of the sample to be tested are broken to denature the protein, degrade the RNA, and denature the DNA into single-stranded DNA to obtain a denatured sample; after the cells are broken, a sodium hydroxide solution with a concentration of 1.75 mol / L and a volume ratio of 1:2 to the sample to be tested is reacted at 65°C for 30 minutes to denature the protein and degrade the RNA, thereby reducing the impact of the protein and RNA on subsequent testing; in addition, the sodium hydroxide solution can also open the double helix structure of DNA and denature and decompose it into single-stranded DNA; in this embodiment, a method combining chemical and physical methods is used to achieve the effect of efficiently degrading RNA and denaturing double-stranded DNA into single-stranded DNA; if the sample to be tested contains bacteria or viruses to be tested, the double-stranded DNA of the double helix structure of the bacteria or virus is denatured and decomposed into single-stranded DNA;

[0065] Step 2, hybridization: the denatured sample obtained in step 1 is mixed with a specific single-stranded RNA probe stored in a nucleic acid preservation solution with a pH value of 3.5-4.0, and hybridized for 45 minutes at a pH value of 7.0-7.4 and a temperature of 65°C to allow the specific single-stranded RNA probe to hybridize with the single-stranded DNA in the denatured sample to form a DNA-RNA hybrid solution; the single-stranded DNA in the denatured sample forms a DNA-RNA hybrid with the single-stranded RNA probe; the specific single-stranded nucleic acid probe is placed in a solution with a pH value of 3.5- 4.0 nucleic acid preservation solution, which helps to keep the specific single-stranded nucleic acid probe stable and not degraded by enzymes in the environment without freezing; when the specific single-stranded nucleic acid probe solution with a pH value of 3.5-4.0 and the sample with an alkaline pH value that is denatured and decomposed into a single-stranded DNA solution are mixed in a certain proportion to form a solution with a neutral pH, the specific single-stranded nucleic acid probe is a single-stranded RNA probe; at 65°C, according to the principle of complementary pairing of base sequences, the single-stranded DNA in the denatured sample and the single-stranded RNA probe form a DNA-RNA hybrid;

[0066] The nucleic acid preservation solution comprises the following components in 100 mL of nucleic acid preservation solution: 5.8-5.95 g of trisodium citrate; 19.56-20.21 g of biological buffer; 0.173-0.192 g of disodium ethylenediaminetetraacetate; 8.2-9.0 ml of acidity regulator; 28-33 μl of preservative; the remainder is pure water; the pH value of the preservation solution is 3.5-4.0; the buffer comprises at least one of triethanolamine hydrochloride and N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid; the acidity regulator comprises at least one of glacial acetic acid and polyacrylic acid;

[0067] The specific single-stranded nucleic acid probe is stored in a nucleic acid storage solution, and the nucleic acid storage solution can be used to store the single-stranded RNA probe without freezing, and can keep the single-stranded RNA probe stable in structure and not easily degraded;

[0068] The specific single-stranded RNA probe can be a full-length single-stranded RNA probe for the target DNA or a fragmented single-stranded RNA probe for a portion of the target DNA; when the specific single-stranded RNA probe is a full-length single-stranded RNA probe for the target DNA, the full-length single-stranded RNA probe for the target DNA is a continuous full-length single-stranded RNA probe for the target DNA or a segmented full-length single-stranded RNA probe for the target DNA; by adopting the above technical scheme, whether it is a full-length single-stranded nucleic acid probe for the target DNA or a fragmented single-stranded RNA probe for a portion of the target DNA, the bases thereon that can form a bond with the single-stranded DNA have a certain specificity, so that the specific single-stranded RNA probe can form a pair with the base on the single-stranded DNA and achieve hybridization of the specific single-stranded RNA probe and the single-stranded DNA, thereby obtaining a DNA-RNA hybrid.

[0069] Step 3, capture: fix the first antibody on the carrier, add the DNA-RNA hybrid solution obtained in step 2, capture the hybrid in the DNA-RNA hybrid solution with the first antibody at a temperature of 42° C. for 60 minutes, and remove the liquid;

[0070] The first antibody is a substance that specifically recognizes the hybrid, and the substance that specifically recognizes the hybrid is a DNA-RNA hybrid structure-specific antibody, a polyclonal antibody or a monoclonal antibody or a fragment thereof, a protein, a catalytically inactivated ribonuclease H, a nucleic acid, a nucleic acid aptamer, or an oligonucleotide that specifically binds to the DNA-RNA hybrid to form a triplex structure; the catalytically inactivated ribonuclease H is a ribonuclease H that loses its catalytic effect after treatment, which is conducive to retaining the binding effect with the DNA-RNA hybrid;

[0071] The main function of the first antibody is to capture the hybrid in the hybrid solution, and reacting at a temperature of 42°C for 60 minutes helps the first antibody to fully capture the hybrid; the second antibody has a marker, which emits fluorescence when it is stimulated by light, or gold particles aggregate and develop color, or enzyme catalyzes the reaction to emit light or develop color, thereby achieving the purpose of detection; the first antibody captures the hybrid, that is, the first antibody binds to the target on the hybrid, the second antibody binds to the DNA-RNA hybrid or hybrid, and is displayed through the marker on the second antibody (in this case, the single-stranded RNA probe does not contain a modifier), thereby detecting the DNA-RNA hybrid and also detecting the target DNA in the sample;

[0072] During the operation of step 3, the first antibody is first fixed on the carrier, which helps to increase the stability of the first antibody during the operation, and when it forms a combination / capture with the hybrid, it helps to improve the stability of the product of the combination of the first antibody and the hybrid obtained by capturing the hybrid on the carrier; when the first antibody and the hybrid are fully combined, other impurities are washed away, leaving the first antibody and the hybrid, and the operation in the subsequent steps is carried out;

[0073] At the same time, the first antibody and the second antibody are self-screened, mainly to minimize the mismatch between the specific single-stranded nucleic acid probe and the target DNA, and to avoid the inactivation of the first antibody and the second antibody as much as possible; among them, when the temperature used for screening the first antibody and the second antibody is set at 42°C, the first antibody and the second antibody obtained at this time have good performance and the required reaction time is short; compared with the temperatures of 25°C and 37°C, the higher temperature of 42°C accelerates the molecular thermal motion, which helps to shorten the time required for the reaction; the second antibody, the first antibody and the hybrid are combined, and the higher temperature can effectively increase the combination between the second antibody, the first antibody and the hybrid, so as to more accurately display the signal-to-noise ratio; compared with the temperatures of 45°C, 50°C and 65°C, at a temperature of 42°C, as the temperature rises higher and higher, the activity of the first antibody and the second antibody gradually decreases or even becomes inactivated, which ultimately makes it difficult to accurately detect the signal-to-noise ratio through the marker carried on the second antibody;

[0074] Step 4, detection: react the DNA-RNA hybrid captured by the first antibody obtained in step 3 with the second antibody stored in the protein storage solution at 42°C for 30 minutes, wash, stand at room temperature in the dark for 10 minutes, and then detect;

[0075] The second antibody is the anti-DNA-RNA hybrid antibody obtained by the method in step S1, and the antibody carries a marker, which emits fluorescence when stimulated by light, or develops color when gold particles aggregate, or emits light or develops color when an enzyme catalyzes a reaction;

[0076] In step 4, the protein preservation solution includes the following components based on 100 ml of the preservation solution: 2.535-3.501 g of sodium chloride; 6-7 ml of Tris-HCl buffer; 20-28 ml of casein solution; 28-31 μl of preservative; the remainder is pure water; the pH value of Tris-HCl is 7.4-7.5;

[0077] In step 4, a second antibody is introduced, and a marker is also marked on the second antibody, and the marker is usually a protein substance. The protein solution is used for storage, which not only does not need to be stored at an extremely low temperature, but also allows the second antibody and the marker marked thereon to maintain good activity, thereby making the detection effect more accurate and true;

[0078] The second antibody is a DNA-RNA hybrid structure-specific antibody, a polyclonal antibody or a monoclonal antibody or a fragment thereof, a protein, a catalytically inactive ribonuclease H, a nucleic acid, a nucleic acid aptamer, or an oligonucleotide that specifically binds to a DNA-RNA hybrid to form a triplex structure;

[0079] The length of the segmented full-length single-stranded RNA probe against the target DNA is greater than 100 bp;

[0080] The length of HPV target DNA is 8000bp, and the single-stranded RNA probe can be a full-length single-stranded RNA probe of 8000bp; or a fragment single-stranded RNA probe of 100-2000bp can be selected. When a fragment single-stranded RNA probe of 2000bp is selected, four single-stranded RNA probes need to be used in combination, namely, 1-2000bp, 2001-4000bp, 4001-6000bp and 6001-8000bp in length;

[0081] And whether it is continuous or segmented, the full-length single-stranded RNA probe can produce a hybrid effect with the single-stranded DNA, thereby obtaining a DNA-RNA hybrid; in addition, the advantage of segmentation is that it is easy to introduce a marker, such as biotin, at the beginning and end of each segmented specific single-stranded nucleic acid probe, and then avidin that specifically binds to biotin can be used to specifically capture biotin and perform subsequent detection, thereby obtaining a better labeling effect; when the length of the segmented full-length single-stranded nucleic acid probe for the target DNA is greater than 100 bp, for example, when the length is 100-2000 bp, it can form base pairing with the single-stranded DNA, thereby causing the single-stranded DNA to form a hybrid with the segmented full-length single-stranded nucleic acid probe for the target DNA;

[0082] Comparative Example

[0083] The anti-DNA-RNA hybrid antibody in the comparative example adopts S9.6 mouse monoclonal antibody, and the remaining steps are the same as those in the example;

[0084] The embodiment and the comparative example were tested on the same test samples, and the experimental results are shown in the following table

[0085]

[0086] The signal-to-noise ratio in the table is the average value of the concentration detection value / the average value of the 0pg / ml detection value. The CV values ​​of the detection values ​​of different concentrations are all below 15%. It can be seen from the signal-to-noise ratio detection results that the background of the antibody in the embodiment is relatively low, and the signal-to-noise ratio is higher than that of the comparative example.

[0087] It should be noted that, in this article, relational terms such as first and second, etc. are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Moreover, the terms "include", "comprise" or any other variants thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or device.

[0088] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A rapid in situ hybridization detection method, characterized in that: The following steps are included: S1. Preparation of anti-DNA-RNA hybrid antibodies; S2, rapid in situ hybridization test; The preparation of the anti-DNA-RNA hybrid antibody in step S1 comprises the following steps: S1.1, immunization of animals; 100 μg / ml DNA-RNA hybrid and 100 μg / ml methylated bovine serum albumin were mixed in 10 ml TE buffer at a mass ratio of 1:1, 30 μg DNA-RNA hybrid was emulsified with Freund's complete adjuvant per Balb / c mouse, and injected subcutaneously in the abdomen, and boosted immunization was performed once on the 14th day and the 28th day respectively. On the 35th day, blood was collected from the mouse tail for detection; S1.2, preparing hybridoma cell lines; taking immune mouse lymphocytes and performing cell fusion and cloning screening to obtain positive hybridoma stable cell lines that can efficiently secrete antibodies, and isolating total RNA from the hybridoma cell lines; S1.3, obtaining antibody sequences; reverse transcribing the total RNA into cDNA, and using specific primers to obtain the nucleotide sequences of the antibody heavy chain variable region and the antibody light chain variable region through PCR amplification technology; S1.

4. Antibody expression and purification: The nucleotide sequence is cloned into an expression vector, and the cultured cells are transiently transfected using a transfection method. After culture, the supernatant is collected and purified using Protein A to obtain an antibody with a purity of >95%.

2. A rapid in situ hybridization detection method according to claim 1, characterized in that: The anti-DNA-RNA hybrid antibody in step S1 is an anti-DNA-RNA hybrid mouse monoclonal antibody, which can specifically recognize any DNA-RNA hybrid.

3. A rapid in situ hybridization detection method according to claim 1, characterized in that: The heavy chain and light chain encoding gene sequences used to encode the anti-DNA-RNA hybrid mouse monoclonal antibody in step S1 are SEQID1 and SEQID2 respectively; the heavy chain and light chain amino acid sequences used to encode the anti-DNA-RNA hybrid mouse monoclonal antibody in step S1 are SEQID3 and SEQID4 respectively.

4. A rapid in situ hybridization detection method according to claim 1, characterized in that: The rapid in situ hybridization detection in step S2 includes the following detection steps: S2.1, dewaxing; drying the tissue sections in a 75°C oven, dewaxing in a dewaxing solution for 5 min × 3 times, treating with 100% ethanol for 3 min × 2 times, treating with 95% ethanol for 2 min, treating with 85% ethanol for 2 min, and soaking in pure water for 2 min; S2.2, protease digestion; shake off the water on the slide, draw circles around the tissue with a water-blocking pen, and wash with phosphate-buffered saline (PBST) buffer for 1 min × 3 times; add 50-100 μl of protease digestion solution, incubate at 37°C for 10-20 min; pour off the protease digestion solution, and wash with PBST for 2 min × 3 times; S2.3, EBER probe hybridization; according to the size of the tissue, add 100-150 μl of EBER probe, place in a wet box, incubate at 37°C for 1-2 hours, and then wash with PBST for 2 minutes × 3 times; S2.4, anti-DNA-RNA hybrid antibody immunization; remove the PBST buffer, add 50-100 μl of horseradish peroxidase (HRP enzyme)-labeled anti-DNA-RNA hybrid antibody to each slice, and incubate at 37°C for 30 min; after the incubation is completed, rinse with PBST buffer for 2 min × 3 times; S2.5, DAB color development: remove PBST buffer, add 100-150 μl of freshly prepared DAB color development solution (DAB concentrate:DAB buffer = 1:19) to each slice, and develop color at room temperature for 3-5 minutes; S2.6, counterstain with hematoxylin; rinse with tap water, add 100-150μl of hematoxylin counterstain, incubate for 1-3min, rinse with tap water to turn blue; dehydrate and make the sections transparent, and seal them as usual; observe the staining of the tissue to be tested under an optical microscope.

5. A rapid in situ hybridization detection method according to claim 4, characterized in that: The main component of the dewaxing solution described in step S2.1 is xylene, and the slices need to be immersed in three bottles of xylene solution for 5 minutes in sequence.

6. A rapid in situ hybridization detection method according to claim 4, characterized in that: The water blocking pen described in step S2.2 is an oily pen, which is used to lock the buffer solution and working solution added subsequently; The concentration of the PBST cleaning solution in step S2.2 is 0.01 mol / L, and the components of 1L solution are as follows: 5.82 g of sodium chloride; 38.81 g of disodium hydrogen phosphate dodecahydrate; 15.60 g of sodium dihydrogen phosphate dihydrate; 200 μl of Tween 20; and the pH value is adjusted to 7.2-7.4; The protease digestion solution in step S2.2 is a solid protease dissolved in a TBS solution, and the BSA solution is 100 ml of a 0.5 mol / L Tris-HCl buffer solution and 3.5 g of NaCl (0.15 mol / L), which are added to make up to 1000 ml.

7. A rapid in situ hybridization detection method according to claim 4, characterized in that: The EBER probe in step S2.3 is a DNA sequence complementary to the EB virus specific target, which is a protective sequence and has a length of 35 bp; The EBER probe length of step S2.3 is 20-100 bp, and the EBER probe length of step S2.3 is one of 15 bp, 35 bp, 100 bp, 500 bp, 1000 bp, and 2000 bp; The wet box in step S2.3 is kept away from light during use, and the color of the wet box is brown or black.

8. A rapid in situ hybridization detection method according to claim 4, characterized in that: The antibody in step S2.4 is purified by a Protien G column and used after being diluted 1000 times with an antibody diluent, wherein the antibody diluent comprises 2.535-3.501 g of sodium chloride, 6-7 ml of Tris-HCl buffer, 20-28 ml of casein solution, 28-31 μl of preservative, and the remainder is pure water; the pH value of Tris-HCl is 7.4-7.5; The antibody in step S2.4 is an anti-DNA-RNA antibody, which is coupled with horseradish peroxidase (HRP), and the HRP can make the DAB color developing solution form a brown precipitate.

9. A rapid in situ hybridization detection method according to claim 4, characterized in that: The DAB color developing solution in step S2.5 should be prepared and used immediately, and the preparation and use time should not exceed 1 hour; The main component of the DAB color developing solution in step S2.5 is diaminobenzidine, and the DAB color developing solution and the DAB diluent must be stored away from light.

10. A rapid in situ hybridization detection application, characterized in that: The invention comprises the use of a rapid in situ hybridization detection method as described in any one of claims 1 to 9 in the detection of anti-DNA-RNA hybrid antibody protein molecules.

Citation Information

Patent Citations

  • Method for quickly and quantitatively detecting target DNA

    CN111979300A

  • EB (Epstein-Barr) virus detection method based on in-situ hybridization method

    CN115125331A

  • In-situ hybridization kit for detecting EB (Epstein-Barr) virus and use method thereof

    CN116590468A

  • Immunochromatography test strip for rapidly detecting HPV16 DNA-RNA heterozygote

    CN118010990A

  • ULBP2 specific chimeric antigen receptor, CAR-T cell and application thereof

    CN119529114A